Staten Island, N.Y. – September 17, 2026 -- Acurx Pharmaceuticals (NASDAQ: ACXP) presented new in vitro data showing its lead antibiotic ibezapolstat achieved a 5.51-log reduction against Clostridioides difficile in co-culture with vancomycin-resistant Enterococcus (VRE), significantly outperforming vancomycin (p=0.0112), the current standard of care.

The poster, presented by Dr. Eugenie Bassères of the University of Houston College of Pharmacy, was unveiled at the 9th International C. difficile Symposium in Bled, Slovenia, held September 8-10, 2026.